By Wolfgang Weiss and Christian Heubeck, Weickmann & Weickmann. This article first appeared in IAM Life Sciences 2017, a supplement to IAM, published by Globe Business Media Group - IP Division.
Obviously as incentive for a withdrawal of applications with low chances of success and/or minor commercial value by the applicants and thus reducing the heavy workload of the EPO, new...
By Michael Dey Ph.D., Frank Feller Ph.D., Weickmann & Weickmann PartmbB and John McDonald Ph.D., J.D., Kilpatrick Townsend & Stockton LLP
Innovator companies in the life sciences field need to protect their technology, which often involves development projects for new medicaments.
On June 23, 2016, the British people decided to leave the European Union. This historic decision not only puts the fate of the Unitary Patent System at stake, but also raises questions with respect to the validity of existing...